Actinogen Medical Limited focuses on the development and commercialization of novel therapeutic compounds, specifically targeting central nervous system diseases. Positioned as an innovative player in the biotechnology sector, Actinogen's flagship product, Xanamem, aims to treat Alzheimer's Disease and other neurodegenerative conditions, offering a unique therapeutic approach in a growing market. ...
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns
Industry & Focus
biotechnology
alzheimers treatment
neuroscience
pharmaceuticals
clinical trials
Company Overview
AI-generated company summary
Actinogen Medical Limited focuses on the development and commercialization of novel therapeutic compounds, specifically targeting central nervous system diseases. Positioned as an innovative player in the biotechnology sector, Actinogen's flagship product, Xanamem, aims to treat Alzheimer's Disease and other neurodegenerative conditions, offering a unique therapeutic approach in a growing market. Their commitment to addressing unmet medical needs through rigorous clinical trials sets them apart from traditional pharmaceutical providers.
Company History
Actinogen Medical Limited was founded in 1999 and has since focused on research in neurosciences, specifically for central nervous system disorders. The company listed on the ASX in 2000, marking its entry into the public trading arena. Over the years, Actinogen has concentrated efforts on the development of Xanamem, a pioneering treatment for Alzheimer's Disease. Notably, the company has achieved several critical preclinical and clinical milestones that underpin their dedication to addressing major health challenges through innovation.
Competitive Advantages
Actinogen Medical possesses a competitive advantage through its proprietary Xanamem drug, which targets the cortisol pathway, offering a novel method to combat Alzheimer's Disease. The company's focus on central nervous system disorders addresses a market with significant unmet needs and growth potential. Additionally, Actinogen's robust clinical trial program enhances its reputation and effectiveness in developing evidence-based treatment solutions.
Risk Factors
•The success of Xanamem is crucial; failure in trials could negatively impact growth.
•Biotechnology sector's dependency on ongoing funding and investment.
•Economic downturns might affect investor interest and stock performance.
Recent Developments
Last 6 months
In the past six months, Actinogen Medical reported positive top-line results from its XanaMIA Part A study, providing crucial insights into Xanamem's potential impact on cognition in older adults. This was a significant advancement towards its development for Alzheimer's Disease. Additionally, the company announced plans to commence Phase II trials, which are critical to moving the drug closer to the market.
Key People
Leadership team at Actinogen Medical
DS
Dr. Steven Gourlay
CEO
Dr. Steven Gourlay joined Actinogen Medical as CEO in December 2020, bringing extensive experience in drug development and clinical research. He has held senior roles at various biotech firms and possesses a strong background in leading clinical stage projects.
MJ
Mr. John Holaday
CFO
Mr. John Holaday has served as the CFO of Actinogen Medical, providing strategic financial leadership and management. He is known for his financial acumen in the biotechnology industry, helping guide companies through various stages of growth and market challenges.
Financial Reports
15 reports available
ACW September 2025 quarterly activity report & Appendix 4C
Quarterly ReportOct 23, 2025via asx_announcements
Annual Report to Shareholders
Annual ReportOct 15, 2025via asx_announcements
ACW Appendix 4E and 2025 annual report
Annual ResultsAug 25, 2025via asx_announcements
Actinogen June 2025 quarterly activity report & Appendix 4C
Quarterly ReportJul 30, 2025via asx_announcements
Actinogen March 2025 quarterly activity report & Appendix 4C
Quarterly ReportApr 30, 2025via asx_announcements
Actinogen HY2025 financial report and Appendix 4D
Half Year ResultsFeb 24, 2025via asx_announcements
ACW December 2024 quarterly activity report & Appendix 4C
Quarterly ReportJan 29, 2025via asx_announcements
ACW September 2024 quarterly activity report & Appendix 4C
